Encompass Health (EHC)

NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-23

$124.09-1.52%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Encompass Health’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.0%

+10% or more+5%0%−5%−10% or less

6.68 → 6.68 EPS · FY ending Dec 31, 2027 · 8 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 8; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	1.67B
EPS	—	1.601
FY 2026 · Annual
operating revenue	$6.41B–$6.49B	—
Revenue	—	6.46B
EPS	$6.02–$6.25non-GAAP	6.112
EBITDA	$1.37B–$1.4Bnon-GAAP	—
FY 2027 · Annual
Revenue	—	6.99B
EPS	—	6.678

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain dividend growth	A supporting condition in Encompass Health's published investment case. The stated target is Dividend per share >= $0.19.	Intact	Dividend per share falls below $0.17 in FY26	Dividend per share: $0.19 per share FY2026-Q2; GAAP. Published target: Dividend per share >= $0.19. Target period is not explicitly aligned with this observation. Source published Aug 7, 20260.19 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: cc6668f7-8fc4-4946-8819-e11ae938f2ce. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Dividend per share increased modestly from $0.17 in 2025-Q2 to $0.19 in 2026-Q2. This steady increase matches management's commitment to maintaining dividend growth, indicating delivering progress. Delivery assessment Oct 24, 2026
Operating income improves via efficiency	Profit rises with better cost control, shown by operating income up $50M year-over-year.	Intact	Operating income falls below $238M in FY26	Operating income: $288.4M FY2026-Q2; GAAP. Published target: Operating income >= $288M. Target period is not explicitly aligned with this observation. Source published Aug 7, 2026288,400,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Operating income increased from $236.8M in 2025-Q2 to $261.6M in 2026-Q2, and Adjusted EBITDA grew from $318.6M to $348.0M. Management's focus on disciplined operating strategy aligns with these improving profitability metrics, indicating delivering progress. Delivery assessment Oct 24, 2026
Revenue grows through organic expansion	A primary condition in Encompass Health's published investment case. The stated target is >=9% YoY revenue growth.	Intact	YoY revenue growth falls below 6% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue increased from $1.4577B in 2025-Q2 to $1.5974B in 2026-Q2 (+9.6%), with discharges growing 5.6%. Management consistently emphasized hospital openings and bed additions to drive organic growth, and the financials show delivering progress. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$6.68

$6.54 → $6.68 · observed estimates

FY2027 revenue$6.99B

$6.94B → $6.99B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$6.54	$6,942,757,474	9 / 10
2026-07-25	$6.54	$6,942,761,490	13 / 12
2026-07-26	$6.54	$6,942,757,474	9 / 10
2026-07-27	$6.54	$6,942,761,490	13 / 12
2026-07-28	$6.54	$6,942,757,474	9 / 10
2026-07-29	$6.54	$6,942,761,490	13 / 12
2026-07-30	$6.54	$6,942,761,490	13 / 12
2026-07-31	$6.54	$6,942,761,490	13 / 12
2026-08-01	$6.54	$6,942,757,474	9 / 10
2026-08-02	$6.54	$6,942,757,474	9 / 10
2026-08-03	$6.54	$6,942,761,490	13 / 12
2026-08-04	$6.54	$6,942,757,474	9 / 10
2026-08-05	$6.54	$6,942,761,490	13 / 12
2026-08-06	$6.54	$6,942,757,474	9 / 10
2026-08-07	$6.57	$6,945,699,320	9 / 9
2026-08-08	$6.61	$6,970,806,320	13 / 12
2026-08-09	$6.61	$6,970,806,320	13 / 12
2026-08-10	$6.61	$6,970,806,320	13 / 12
2026-08-11	$6.57	$6,945,699,320	9 / 9
2026-08-12	$6.57	$6,945,699,320	9 / 9
2026-08-13	$6.68	$6,993,645,070	13 / 12
2026-08-14	$6.57	$6,945,699,320	9 / 9
2026-08-15	$6.57	$6,945,699,320	9 / 9
2026-08-16	$6.57	$6,945,699,320	9 / 9
2026-08-17	$6.57	$6,945,699,320	9 / 9
2026-08-18	$6.57	$6,945,699,320	9 / 9
2026-08-19	$6.57	$6,945,699,320	9 / 9
2026-08-20	$6.68	$6,994,328,400	8 / 10
2026-08-21	$6.68	$6,994,328,400	8 / 10
2026-08-22	$6.68	$6,994,328,400	8 / 10
2026-08-23	$6.68	$6,994,328,400	8 / 10
2026-08-24	$6.68	$6,994,328,400	8 / 10
2026-08-25	$6.68	$6,994,328,400	8 / 10
2026-08-26	$6.68	$6,994,328,400	8 / 10
2026-08-27	$6.68	$6,994,328,400	8 / 10
2026-08-28	$6.68	$6,994,328,400	8 / 10
2026-08-29	$6.68	$6,994,328,400	8 / 10
2026-08-30	$6.68	$6,994,328,400	8 / 10
2026-08-31	$6.68	$6,994,328,400	8 / 10
2026-09-01	$6.68	$6,994,328,400	8 / 10
2026-09-02	$6.68	$6,994,328,400	8 / 10
2026-09-03	$6.68	$6,994,328,400	8 / 10
2026-09-04	$6.68	$6,994,328,400	8 / 10
2026-09-05	$6.68	$6,994,328,400	8 / 10
2026-09-06	$6.68	$6,994,328,400	8 / 10
2026-09-07	$6.68	$6,994,328,400	8 / 10
2026-09-08	$6.68	$6,994,328,400	8 / 10
2026-09-09	$6.68	$6,994,328,400	8 / 10
2026-09-10	$6.68	$6,994,328,400	8 / 10
2026-09-11	$6.68	$6,994,328,400	8 / 10
2026-09-12	$6.68	$6,994,328,400	8 / 10
2026-09-13	$6.68	$6,994,328,400	8 / 10
2026-09-14	$6.68	$6,994,328,400	8 / 10
2026-09-15	$6.68	$6,994,328,400	8 / 10
2026-09-16	$6.68	$6,994,328,400	8 / 10
2026-09-17	$6.68	$6,994,328,400	8 / 10
2026-09-18	$6.68	$6,994,328,400	8 / 10
2026-09-19	$6.68	$6,994,328,400	8 / 10
2026-09-20	$6.68	$6,994,328,400	8 / 10
2026-09-21	$6.68	$6,994,328,400	8 / 10
2026-09-22	$6.68	$6,994,328,400	8 / 10
2026-09-23	$6.68	$6,994,328,400	8 / 10
2026-09-24	$6.68	$6,994,328,400	8 / 10
2026-09-25	$6.68	$6,994,328,400	8 / 10
2026-09-26	$6.68	$6,994,328,400	8 / 10
2026-09-27	$6.68	$6,994,328,400	8 / 10
2026-09-28	$6.68	$6,994,328,400	8 / 10
2026-09-29	$6.68	$6,994,328,400	8 / 10
2026-09-30	$6.68	$6,994,328,400	8 / 10
2026-10-01	$6.68	$6,994,328,400	8 / 10
2026-10-02	$6.68	$6,994,328,400	8 / 10
2026-10-03	$6.68	$6,994,328,400	8 / 10
2026-10-04	$6.68	$6,994,425,833	8 / 10
2026-10-05	$6.68	$6,994,425,833	8 / 10
2026-10-06	$6.68	$6,994,428,400	8 / 10
2026-10-07	$6.68	$6,994,428,400	8 / 10
2026-10-08	$6.68	$6,994,428,400	8 / 10
2026-10-09	$6.68	$6,994,428,400	8 / 10
2026-10-10	$6.68	$6,994,428,400	8 / 10
2026-10-11	$6.68	$6,994,428,400	8 / 10
2026-10-12	$6.68	$6,994,428,400	8 / 10
2026-10-13	$6.68	$6,994,425,833	8 / 10
2026-10-14	$6.68	$6,994,425,833	8 / 10
2026-10-15	$6.68	$6,994,425,833	8 / 10
2026-10-16	$6.68	$6,994,425,833	8 / 10
2026-10-17	$6.68	$6,994,425,833	8 / 10
2026-10-18	$6.68	$6,994,425,833	8 / 10
2026-10-19	$6.68	$6,994,425,833	8 / 10
2026-10-20	$6.68	$6,994,425,833	8 / 10
2026-10-21	$6.68	$6,994,425,833	8 / 10
2026-10-22	$6.68	$6,994,425,833	8 / 10
2026-10-23	$6.68	$6,994,425,833	8 / 10
2026-10-24	$6.68	$6,994,425,833	8 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	13	0	0
2026-06-01	13	0	0
2026-07-01	13	0	0
2026-08-01	13	0	0
2026-09-01	13	0	0
2026-10-01	13	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesSep 28

$150.00New observation · no comparable prior

$0$82.50$165.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain dividend growthDividend per share: $0.19 per share
Operating income improves via efficiencyOperating income: $288.4M
Revenue grows through organic expansionDirect metric needs a verified mapping

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.7%Typical daily move · historical

Downside history

-26.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Encompass Health outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

EHC is a growing hospital operator with a thesis tied to continued organic growth and improved operating income. Its recent results are strong and management priorities appear on track, though management execution has been volatile. The current long-term thesis is intact.

What's priced into Encompass Health

The valuation evidence points to EHC being cheap versus peers, with a small expectations gap and no signs of fragile pricing. However, model confidence is low, so the valuation signal is uncertain. The evidence does not show that the market assumes unusually strong growth.

What the fundamentals likely do

In the near term, recent results show revenue, operating income, and adjusted EBITDA growing, alongside higher discharges and a modest dividend increase. Management has raised guidance, and the recent earnings event was positive, but a reversal and guidance cut would damage credibility. A weakening jobs report could also add pressure through recession concerns.

What Encompass Health hinges on

Over the next one to three years, the thesis hinges on continued hospital openings and bed additions translating into revenue growth, while disciplined operations support profitability. A guidance cut after the recent increase is a key unfavorable scenario. Continued earnings strength and higher guidance from healthcare bellwethers would support the sector backdrop.